NEW YORK (GenomeWeb News) — Shares in Decode Genetics were up 10 percent, or $.35, at $3.87 after the stock was upgraded by an investment bank
Lehman Brothers upgraded the stock to "equal-weight" from "underweight."
Decode yesterday reported that fourth-quarter revenues increased 17 percent as R&D spending rose 4 percent and lossed increased 10 percent. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.